Medscape Pioglitazone, a thiazolidinedione (TZD) for the treatment of type 2 diabetes, has been associated with a number of adverse effects, including fractures and fluid retention, and is contraindicated in patients with class 3 or 4 heart failure. But it has ... and more »
Medscape This observational cohort study sought to determine the effect of initial oral glucose-lowering class on subsequent need for additional anti-hyperglycemia therapy. Participants included 15,516 patients who were not previously treated for diabetes, in ...
FDA.gov The U.S. Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar lev...
Endocrinology Update Of these, 25% needed a second oral medication . The need for secondary medication was 37% for sulfonylureas, 39% for thiazolidinedione and 36% for those prescribed a dipeptidyl peptidase 4 inhibitor (DPP-4 inhibitor). Five per cent of patients ...
Diabetes News Journal Researchers used the information from medical and prescription insurance claims, and concluded that individuals treated with sulfonylurea (SFU), dipeptidyl peptidase-4 (DPP-4) inhibitor, and thiazolidinedione (TZD) were significantly more likely to ...
Health24.com Of those patients, almost 60 percent were initially treated with metformin, and about one-quarter began treatment with a sulfonylurea, such as Glucotrol, according to the study. Just 6 percent were started with a thiazolidinedione , such as Actos, and ... and more »
PR Newswire (press release) Actos has been a prescribed diabetes medication since 1999 and is type of thiazolidinedione (TZD) that has been connected to a variety of side effects such as bladder cancer, cardiovascular problems, liver issues and fractures. Often individuals and ... and more »
